SPMED Co., Ltd. is proud to announce its successful participation in the 2025 International Society for the Study of Xenobiotics (ISSX), held from September 21 to 24, 2025. Following our presence at the 2024 ISSX in Hawaii, we returned this year to share our latest research achievements and engage with global researchers and industry partners.

This year’s conference, centered on "Metabolism and Transporter Research for Drug Discovery," brought together leading pharmaceutical companies and world-class research institutions from across the globe.

Key Highlights from ISSX 2025:

• Promoting Innovative Technology: We showcased SPMED’s differentiated CRO solutions and technologies designed to streamline drug development, drawing significant attention from global industry stakeholders.
  

• Technical Consultations: Leveraging our specialized expertise in drug metabolism and pharmacogenomics, we conducted in-depth technical consultations with numerous international pharmaceutical firms and research teams.
  

• Expanding Global Networks: By discussing joint research and strategic partnerships with experts from around the world, we have laid a solid foundation for SPMED’s advanced technologies to penetrate and lead the global market.
  

"Participating in ISSX 2025 was a valuable opportunity to reaffirm SPMED’s world-class competitiveness on the global stage. We extend our deepest gratitude to all the partners and researchers who visited our booth and showed interest in our work."

Based on the valuable feedback and networking gained during the event, SPMED remains committed to evolving as a global leader in precision medicine, driving innovation in the international drug discovery market.

Thank you.